Pfizer Inc. (PFE) News

Pfizer delivered a highly constructive first quarter in 2026, punctuated by strong execution across its strategic acquisitions and a significant legal victory that dramatically improves its long-term growth profile. The pharmaceutical giant is successfully transitioning its revenue base away from COVID-19 products, achieving robust operational growth in its underlying business. Management highlighted that early returns from major acquisitions, particularly Seagen and Biohaven, are providing the necessary momentum to offset upcoming patent expirations later in the decade.

Pfizer's fourth-quarter and full-year 2025 results demonstrated exactly what management had promised: a company fundamentally realigning for a new era of growth. While total annual revenues slightly declined due to the final unwinding of COVID-19 product sales, the core business grew a robust 6%. The quarter was defined by massive strategic moves, taking a $4.4 billion non-cash impairment to aggressively prune the pipeline while simultaneously presenting compelling data that positions Pfizer to disrupt the massive obesity market with the industry's first potential once-a-month GLP-1 injection.